New Guidance from the FDA Intends to Improve Cancer Clinical Trials for Accelerated Approval
source: shutterstock.com

New Guidance from the FDA Intends to Improve Cancer Clinical Trials for Accelerated Approval

According to a press release from the US Food and Drug Administration (FDA), on March 24, 2023, the agency issued a new draft guidance titled Clinical Trial Considerations to Support Accelerated…

Continue Reading New Guidance from the FDA Intends to Improve Cancer Clinical Trials for Accelerated Approval
FDA Grants Accelerated Approval to Combination Treatment for Patients with Advanced or Metastatic Urothelial Carcinoma
source: shutterstock.com

FDA Grants Accelerated Approval to Combination Treatment for Patients with Advanced or Metastatic Urothelial Carcinoma

  According to reporting for Cure Today, the FDA recently granted Accelerated Approval to a combination treatment of Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) for advanced or metastatic urothelial carcinoma.…

Continue Reading FDA Grants Accelerated Approval to Combination Treatment for Patients with Advanced or Metastatic Urothelial Carcinoma
Acral Lentiginous Melanoma (ALM) Rates Higher in Southeast Asian Individuals than Other Asian Groups
source: unsplash.com

Acral Lentiginous Melanoma (ALM) Rates Higher in Southeast Asian Individuals than Other Asian Groups

  In the past, there has been limited research exploring the presentation of melanoma in Asian American and Pacific Islanders (AAPIs). Recent research has sought to explore this relationship and…

Continue Reading Acral Lentiginous Melanoma (ALM) Rates Higher in Southeast Asian Individuals than Other Asian Groups
Ipsen Pushes for FDA Approval of Palovarotene for FOP
source: pixabay.com

Ipsen Pushes for FDA Approval of Palovarotene for FOP

In 2022, the U.S. Food and Drug Administration (FDA) examined the potential of approving palovarotene, a selective RARγ agonist, for the treatment of fibrodysplasia ossificans progressiva (FOP). However, the FDA…

Continue Reading Ipsen Pushes for FDA Approval of Palovarotene for FOP
NICE Guidance Recommends Upstaza for AADC Deficiency
source: shutterstock

NICE Guidance Recommends Upstaza for AADC Deficiency

  In November 2022, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved Upstaza (eladocagene exuparvovec) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. The product, which…

Continue Reading NICE Guidance Recommends Upstaza for AADC Deficiency
Lipoprotein(a) Awareness Day is March 24: Spreading Awareness About an Underrecognized Condition
source: pixabay.com

Lipoprotein(a) Awareness Day is March 24: Spreading Awareness About an Underrecognized Condition

March 24 is being recognized this year as Lipoprotein(a) Awareness Day, a time to spread awareness among the general public and the medical field about elevated lipoprotein(a), a condition which…

Continue Reading Lipoprotein(a) Awareness Day is March 24: Spreading Awareness About an Underrecognized Condition